Kristie L. Kahl | Authors


Prolonged Duration of Response With Tivozanib for RCC Revealed at Long-Term Follow-Up

June 04, 2021

Follow-up data from the phase 3 TIVO-3 trial that were reported at the 2021 ASCO Annual Meeting serve to further support the use of tivozanib versus standard-of-care sorafenib in patients with metastatic renal cell carcinoma who have failed on prior therapy.